The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
Asch R, Hillmer A, Baldassarri S, Esterlis I. The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders. International Review Of Neurobiology 2022, 168: 265-310. PMID: 36868631, DOI: 10.1016/bs.irn.2022.10.007.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersGlutamatesHumansMental DisordersMood DisordersReceptor, Metabotropic Glutamate 5ConceptsPsychiatric disordersMetabotropic glutamate receptor 5Positron emission tomography studyGlutamate receptor 5Utility of PETEmission tomography studiesPromising therapeutic targetStress-related disordersNumerous psychiatric disordersTreatment trialsGlutamate neurotransmissionGlutamate systemMGlu5 expressionSubtype 5Treatment responseMood disordersRole of mGlu5Receptor 5Therapeutic targetPsychiatric conditionsMGlu5Tomography studySubstance useTrauma disordersDisorders
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply